Hospira Pty Ltd and Minister for Health

This matter concerned an application by Hospira Pty Ltd against the Minister for Health. The dispute arose from the registration of biological medications, specifically concerning the assessment and registration of biosimilar medications. The Tribunal acknowledged that confidentiality orders had been made regarding certain documents and evidence due to the presence of commercially sensitive information.

The primary legal issue before the Tribunal was the interpretation of amendments to the Act concerning the registration of biological medications. These amendments, introduced in 2014, allowed for the assessment and registration of biological medications based on their biosimilarity to medications already approved by international regulatory authorities such as the European Medicines Agency. The Tribunal was required to determine how these provisions applied in the context of medications with the same active component but produced through different manufacturing processes.

The Tribunal noted that while the amendments permitted registration based on biosimilarity, the evidence demonstrated that no two batches of a biological medication, let alone those produced by different manufacturers, could be bio-identical. This was attributed to the complex manufacturing processes involving human cells, animal hosts, and various chemical components. The Tribunal highlighted that Hospira's product, INFLECTRA™, and Janssen's Remicade®, both containing Infliximab, were biosimilar but not bio-identical. The Tribunal's decision on the question of statutory interpretation was not detailed in the provided text.